CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)

12 Health Care Stocks Moving In Monday's Intraday Session

These stocks are moving in today's pre-market session

CervoMed Shows Progress in Treating Rare Aphasia Condition

CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session

CervoMed Announces Data From Its Phase 2a Clinical Study Of Nonfluent Variant Primary Progressive Aphasia Shows Reduction In Mean Plasma Levels Of Neurofilament Light Chain

A rare dementia can take away speech; no drug is approved for it. CervoMed saw a nerve-damage marker fall over 12 weeks.

HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

Hopeful Week For Insiders Who Bought US$3.46m Of CervoMed Stock

CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

CervoMed to Participate in September Investor Conferences

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia